MediciNova, Inc. Form 10-Q Summary
Business Context and Reporting Period
MediciNova is a clinical-stage biopharmaceutical company developing small-molecule therapeutics for serious diseases with unmet medical needs. Key programs include MN-166 for neurological disorders, MN-221 for acute asthma exacerbations, MN-001 for NASH, and MN-029 for solid tumors. This unaudited filing covers the quarter and six months ended June 30, 2014.
Financial Performance and Position
| Metric | Three Months Ended June 30, 2014 | Six Months Ended June 30, 2014 |
|---|---|---|
| Revenue | $0 | $0 |
| Research, development and patent expense | $0.8 million | $1.6 million |
| General and administrative expense | $1.3 million | $2.9 million |
| Operating loss | $2.1 million | $4.5 million |
| Net loss attributable to common stockholders | $2.1 million | $4.5 million |
| Basic and diluted loss per share | $0.09 | $0.19 |
| Operating cash flow | Not separately provided for the quarter | $3.4 million provided |
- Cash and cash equivalents were $13.5 million at June 30, 2014, compared with $6.7 million at December 31, 2013.
- Working capital was $13.3 million at June 30, 2014.
- Total assets were $29.6 million and total liabilities were $4.8 million. The filing does not report conventional debt; liabilities primarily consisted of accrued expenses, deferred taxes, deferred revenue and lease obligations.
- Accumulated deficit was $305.9 million. The filing does not provide a meaningful revenue-based margin because revenue was zero during the quarter and year-to-date period.
- Operating cash flow benefited from collection of a $6.0 million Genzyme-related receivable recorded in 2013. Financing activities provided $3.4 million, principally from common-stock issuance and warrant exercises.
Material Changes Versus Prior Comparable Period
- Second-quarter net loss decreased to $2.1 million from $2.8 million, primarily because general and administrative expense declined by $0.5 million to $1.3 million.
- Six-month net loss decreased to $4.5 million from $5.2 million. General and administrative expense declined by $0.7 million, while research and development expense was broadly unchanged.
- Six-month operating cash flow changed from $4.7 million used in 2013 to $3.4 million provided in 2014, mainly due to collection of the $6.0 million Genzyme receivable and cost containment.
- Six-month financing proceeds declined to $3.4 million from $12.8 million in the prior-year period.
- Common shares outstanding increased to 24.1 million at June 30, 2014 from 22.5 million at December 31, 2013. The company sold 1.55 million shares under its at-the-market facility during the six months.
- Revenue fell to zero for the six months from $3,257 in the prior-year period. No revenue was recognized in either second quarter.
Outlook, Commentary, Risks and Unusual Items
- Management expects substantial net losses to continue for the next several years while product candidates are developed.
- Management stated that available working capital was expected to fund operations through at least June 30, 2015, but cautioned that resources may not fund all planned research and development programs.
- The company is pursuing additional financing through equity sales and strategic initiatives. Failure to obtain financing could require selling programs or ceasing operations.
- Development activities are focused particularly on advancing MN-166 through investigator-sponsored, government-funded and grant-supported trials, including the SPRINT-MS Phase 2 trial.
- The company intends to seek strategic pharmaceutical partnerships after proof-of-concept clinical trials, but no assurance is provided that partnerships will be completed.
- The Zhejiang Sunmy joint venture remains subject to Chinese government approval of a proposed ownership change, and no sublicense of MN-221 had been executed as of the filing date.
- Goodwill of $9.6 million and in-process research and development of $4.8 million are indefinite-lived assets subject to impairment testing.
- The filing reports no material legal proceedings, no material changes to previously disclosed risk factors, and no subsequent events requiring recognition or disclosure.
- Disclosure controls and procedures were assessed as effective at the reasonable-assurance level, with no material change in internal control over financial reporting.
Important Facts for Investors to Verify
- Whether the company can continue funding clinical development using its $13.5 million cash balance and additional equity or strategic financing.
- The timing, cost and results of MN-166, MN-221, MN-001 and MN-029 clinical and development programs.
- Potential dilution from the 24.1 million common shares outstanding, 3.3 million stock options, 3.7 million warrants and 2.2 million shares issuable upon conversion of preferred stock.
- Whether the Genzyme-related economics generate additional milestone, sublicense or royalty payments.
- Whether the Zhejiang Sunmy ownership amendment receives Chinese government approval and whether the MN-221 sublicense is executed.
- Potential impairment of goodwill and in-process research and development if development programs do not progress or expected future cash flows decline.